Patents Assigned to Alba Therapeutics Corporation
-
Patent number: 11149063Abstract: Novel compounds and methods for the inhibition of biological barrier permeability and for the inhibition of peptide translocation across biological barriers are identified. Assays for determining modulators of biological barrier permeability and for peptide translocation across biological barriers are provided. Methods for treating diseases relating to aberrant biological barrier permeability and peptide translocation across biological barriers are provided. Such diseases include celiac disease, necrotizing enterocolitis, diabetes, cancer, inflammatory bowel diseases, asthma, COPD, excessive or undesirable immune response, gluten sensitivity, gluten allergy, food allergy, rheumatoid arthritis, multiple sclerosis, immune-mediated or type 1 diabetes mellitus, systemic lupus erythematosus, psoriasis, scleroderma and autoimmune thyroid diseases.Type: GrantFiled: November 22, 2019Date of Patent: October 19, 2021Assignee: ALBA THERAPEUTICS CORPORATIONInventors: Sefik Alkan, Amir Tamiz, Kelly Marie Kitchens, Malarvizhi Durai, Neil Poloso, Rosa A. Carrasco
-
Patent number: 10723763Abstract: The present application provides compositions and methods for treating acute lung injury and acute respiratory distress syndrome. The methods include administering one or more tight junction antagonists to the lung of a subject in need thereof.Type: GrantFiled: August 12, 2016Date of Patent: July 28, 2020Assignees: ALBA THERAPEUTICS CORPORATION, UNIVERSITY OF MARYLAND, BALTIMOREInventors: Blake Paterson, Peter Ward, Alessio Fasano
-
Patent number: 10526372Abstract: Novel compounds and methods for the inhibition of biological barrier permeability and for the inhibition of peptide translocation across biological barriers are identified. Assays for determining modulators of biological barrier permeability and for peptide translocation across biological barriers are provided. Methods for treating diseases relating to aberrant biological barrier permeability and peptide translocation across biological barriers are provided. Such diseases include celiac disease, necrotizing enterocolitis, diabetes, cancer, inflammatory bowel diseases, asthma, COPD, excessive or undesirable immune response, gluten sensitivity, gluten allergy, food allergy, rheumatoid arthritis, multiple sclerosis, immune-mediated or type 1 diabetes mellitus, systemic lupus erythematosus, psoriasis, scleroderma and autoimmune thyroid diseases.Type: GrantFiled: January 2, 2018Date of Patent: January 7, 2020Assignee: ALBA THERAPEUTICS CORPORATIONInventors: Sefik Alkan, Amir Tamiz, Kelly Marie Kitchens, Malarvizhi Durai, Neil Poloso, Rosa A. Carrasco
-
Patent number: 9279807Abstract: The present invention provides materials and methods for the treatment of celiac disease. In addition, the present invention provides materials and methods of monitoring the treatment of a subject having celiac disease.Type: GrantFiled: August 22, 2011Date of Patent: March 8, 2016Assignees: ALBA THERAPEUTICS CORPORATION, UNIVERSITY OF MARYLAND, BALTIMOREInventors: Alessio Fasano, Blake Paterson
-
Patent number: 9265811Abstract: Enteric compositions comprising one or more tight junction agonists and/or one or more tight junction antagonists are provided. Compositions of the invention may comprise a delayed-release coating disposed over a tight junction agonist and/or tight junction antagonist layer which may be disposed over an inert core. Delayed-release coatings may be substantially stable in gastric fluid and substantially unstable in intestinal fluid, thus providing for substantial release of the tight junction agonist and/or antagonist from the composition in the duodenum or jejunum of the small intestine.Type: GrantFiled: February 9, 2007Date of Patent: February 23, 2016Assignee: ALBA THERAPEUTICS CORPORATIONInventors: Blake Paterson, Mark J. Ginski
-
Patent number: 9051349Abstract: The invention provides crystalline forms of the peptide Gly-Gly-Val-Leu-Val-Gln-Pro-Gly (SEQ ID NO 1), and salts of the peptide, which may further have associated water molecules. These salts and hydrated salts of the peptide and compositions comprising these materials have advantageous pharmaceutical properties.Type: GrantFiled: March 15, 2013Date of Patent: June 9, 2015Assignee: Alba Therapeutics CorporationInventors: Roland Callens, Georges Blondeel, Thierry Delplanche
-
Patent number: 8957032Abstract: Novel compounds and methods for the inhibition of biological barrier permeability and for the inhibition of peptide translocation across biological barriers are identified. Assays for determining modulators of biological barrier permeability and for peptide translocation across biological barriers are provided. Methods for treating diseases relating to aberrant biological barrier permeability and peptide translocation across biological barriers are provided. Such diseases include celiac disease, necrotizing enterocolitis, diabetes, cancer, inflammatory bowel diseases, asthma, COPD, excessive or undesirable immune response, gluten sensitivity, gluten allergy, food allergy, rheumatoid arthritis, multiple sclerosis, immune-mediated or type 1 diabetes mellitus, systemic lupus erythematosus, psoriasis, scleroderma and autoimmune thyroid diseases.Type: GrantFiled: May 6, 2009Date of Patent: February 17, 2015Assignee: Alba Therapeutics CorporationInventors: Sefik Alkan, Amir Tamiz, Kelly Marie Kitchens, Malarvizhi Durai, Neil Poloso, Rosa A. Carrasco
-
Publication number: 20140294894Abstract: The present invention provides materials and methods to facilitate the transcutaneous delivery of therapeutic agents. In some embodiments, agonists of tight junctions are used in compositions to facilitate the uptake of therapeutic agents from the skin. In a particular embodiment, the present invention provides immunogenic compositions comprising a tight junction agonist and an antigen. In a particular embodiment, the present invention provides vaccine compositions comprising a tight junction agonist and an antigen.Type: ApplicationFiled: April 2, 2014Publication date: October 2, 2014Applicant: Alba Therapeutics CorporationInventors: Dorothea Sesardic, Blake Paterson
-
Patent number: 8796203Abstract: The present invention provides materials and methods for the treatment of inflammatory bowel disease (e.g., Crohn's disease and ulcerative colitis). Materials of the invention may include compositions comprising one or more tight junction antagonists and optionally one or more therapeutic agents. Methods of the invention may comprise treating a subject in need thereof with a composition comprising one or more tight junction antagonists and, optionally one or more therapeutic agents.Type: GrantFiled: September 24, 2012Date of Patent: August 5, 2014Assignee: Alba Therapeutics CorporationInventors: Blake Paterson, Amir Tamiz, Niranjan Pandey
-
Patent number: 8785374Abstract: The present invention provides novel peptides that inhibit and/or reduce the opening of mammalian tight junctions, i.e. peptide tight junction antagonists. The present invention also provides methods for the treatment of excessive or undesirable permeability of a tissue by administering to a subject suffering from such a condition a composition comprising a peptide tight junction antagonist of the invention.Type: GrantFiled: October 20, 2008Date of Patent: July 22, 2014Assignee: Alba Therapeutics CorporationInventor: Amir Tamiz
-
Publication number: 20140171377Abstract: The present invention provides novel peptides that facilitate the opening of mammalian tight junctions, i.e. tight junction agonists. The present invention also provides methods for the treatment of disease by administering to a subject suffering from the disease a composition comprising a peptide tight junction agonist of the invention in combination with a therapeutically effective amount of an active agent.Type: ApplicationFiled: September 10, 2013Publication date: June 19, 2014Applicant: Alba Therapeutics CorporationInventors: Amir Tamiz, Min Li
-
Patent number: 8728491Abstract: The present invention provides materials and methods to facilitate the transcutaneous delivery of therapeutic agents. In some embodiments, agonists of tight junctions are used in compositions to facilitate the uptake of therapeutic agents from the skin. In a particular embodiment, the present invention provides immunogenic compositions comprising a tight junction agonist and an antigen. In a particular embodiment, the present invention provides vaccine compositions comprising a tight junction agonist and an antigen.Type: GrantFiled: May 7, 2008Date of Patent: May 20, 2014Assignee: Alba Therapeutics CorporationInventors: Dorothea Sesardic, Blake Paterson
-
Publication number: 20130295594Abstract: The present invention provides methods and materials, including kits, to evaluate Crohn's disease, including to diagnose, monitor, or determine the efficacy of treatment for Crohn's Disease. The methods involve determining the presence, absence, or level of zonulin in a subject sample. In certain embodiments, the need for more laborious and/or invasive tests to monitor disease state is minimized or obviated.Type: ApplicationFiled: May 1, 2012Publication date: November 7, 2013Applicants: Alba Therapeutics Corporation, University of Maryland, BaltimoreInventors: Julio Bai, Alessio Fasano, Blake Paterson, Alicia Sambueli
-
Publication number: 20130288950Abstract: The present application provides compositions and methods for treating acute lung injury and acute respiratory distress syndrome. The methods include administering one or more tight junction antagonists to the lung of a subject in need thereof.Type: ApplicationFiled: March 28, 2013Publication date: October 31, 2013Applicants: ALBA THERAPEUTICS CORPORATION, UNIVERSITY OF MARYLAND, BALTIMOREInventors: Blake Paterson, Peter Ward, Alessio Fasano
-
Patent number: 8557763Abstract: The present invention provides novel peptides that facilitate the opening of mammalian tight junctions. i.e. tight junction agonists. Th present invention also provides methods for the treatment of disease by administering to a subject suffereing from the disease a composition comprising a peptide tight junction agonist of the invention in combination with a therapeutically effective amount of an active agent.Type: GrantFiled: May 18, 2012Date of Patent: October 15, 2013Assignee: Alba Therapeutics CorporationInventors: Amir Tamiz, Min Li
-
Publication number: 20130122086Abstract: Enteric compositions comprising one or more tight junction agonists and/or one or more tight junction antagonists are provided. Compositions of the invention may comprise a delayed-release coating disposed over a tight junction agonist and/or tight junction antagonist layer which may be disposed over an inert core. Delayed-release coatings may be substantially stable in gastric fluid and substantially unstable in intestinal fluid, thus providing for substantial release of the tight junction agonist and/or antagonist from the composition in the duodenum or jejunum of the small intestine.Type: ApplicationFiled: April 18, 2012Publication date: May 16, 2013Applicant: Alba Therapeutics CorporationInventors: Blake Paterson, Mark J. Ginski
-
Publication number: 20120322748Abstract: The present invention provides novel peptides that facilitate the opening of mammalian tight junctions. i.e. tight junction agonists. The present invention also provides methods for the treatment of disease by administering to a subject suffering from the disease a composition comprising a peptide tight junction agonist of the invention in combination with a therapeutically effective amount of an active agent.Type: ApplicationFiled: May 18, 2012Publication date: December 20, 2012Applicant: Alba Therapeutics CorporationInventors: Amir Tamiz, Min Li
-
Patent number: 8198233Abstract: The present invention provides novel peptides that facilitate the opening of mammalian tight junctions, i.e. tight junction agonists. The present invention also provides methods for the treatment of disease by administering to a subject suffering from the disease a composition comprising a peptide tight junction agonist of the invention in combination with a therapeutically effective amount of an active agent.Type: GrantFiled: July 28, 2008Date of Patent: June 12, 2012Assignee: Alba Therapeutics CorporationInventors: Amir Tamiz, Min Lin
-
Patent number: 8168594Abstract: Enteric compositions comprising one or more tight junction agonists and/or one or more tight junction antagonists are provided. Compositions of the invention may comprise a delayed-release coating disposed over a tight junction agonist and/or tight junction antagonist layer which may be disposed over an inert core. Delayed-release coatings may be substantially stable in gastric fluid and substantially unstable in intestinal fluid, thus providing for substantial release of the tight junction agonist and/or antagonist from the composition in the duodenum or jejunum of the small intestine.Type: GrantFiled: November 11, 2009Date of Patent: May 1, 2012Assignee: Alba Therapeutics CorporationInventors: Blake Paterson, Mark J. Ginski
-
Publication number: 20120076861Abstract: The present invention provides materials and methods for the treatment of celiac disease. In addition, the present invention provides materials and methods of monitoring the treatment of a subject having celiac disease.Type: ApplicationFiled: August 22, 2011Publication date: March 29, 2012Applicants: University of Maryland, Baltimore, Alba Therapeutics CorporationInventors: Alessio FASANO, Blake Paterson